סיגניפור לאר 20 מג
medison pharma ltd - pasireotide as embonate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as embonate 20 mg/vial - pasireotide
סיגניפור לאר 40 מג
medison pharma ltd - pasireotide as embonate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as embonate 40 mg/vial - pasireotide
סיגניפור לאר 60 מג
medison pharma ltd - pasireotide as embonate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as embonate 60 mg/vial - pasireotide
סיגניפור לאר 10 מג
medison pharma ltd - pasireotide as pamoate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as pamoate 10 mg/vial - pasireotide
סיגניפור לאר 30 מג
medison pharma ltd - pasireotide as pamoate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as pamoate 30 mg/vial - pasireotide
רמיטנס 2.5
rafa laboratories ltd - ramipril 2.5 mg - capsules - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.
רמיטנס 5
rafa laboratories ltd - ramipril 5 mg - capsules - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.
רמיטנס 10
rafa laboratories ltd - ramipril - קפסולות - ramipril 10 mg - ramipril - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.
רמיפריל טבע 10 מג
teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 10 mg - ramipril - ramipril - hypertension . congestive heart failure . reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.
רמיפריל טבע 5 מג
teva pharmaceutical industries ltd, israel - ramipril - טבליה - ramipril 5 mg - ramipril - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.